Cancer patient 1st to be treated under Right to Try

A patient in California is now the first person in the U.S. to use an experimental treatment secured through the Right to Try Act, reports Regulatory Focus.

President Donald Trump signed the Right to Try Act into federal law in May 2018. The law gives patients with life-threatening conditions the opportunity to access experimental treatments without FDA authorization.

The patient was diagnosed with an aggressive form of brain cancer and began using the experimental treatment ERC-1671 at University of California, Irvine in November 2018. ERC-USA is developing the experimental drug, which is currently in phase 2 clinical trials. The patient sought to access the drug through the Right to Try Act after failing to qualify for an ongoing clinical trial.

More articles on clinical leadership and infection control:
Late-career physicians more likely to prescribe long antibiotic courses
Rare, drug-resistant infection found in Wyoming hospital patient
More NPs giving primary care in places underserved by physicians, study finds


© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


IC Database-3

Top 40 Articles from the Past 6 Months